SUPERNUS PHARMACEUTICALS, INC. (SUPN) Operating income 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) annual operating income history from SEC filings — each fiscal year as reported.
-$62.3MFY2025 · since FY2016: $54.2M → -$62.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$62.3M | -176.3% |
| FY2024 | $81.7M | +1649.9% |
| FY2023 | -$5.3M | -111.4% |
| FY2022 | $46.1M | -46.4% |
| FY2021 | $86.0M | -50.5% |
| FY2020 | $173.7M | +16.9% |
| FY2019 | $148.6M | +2.9% |
| FY2018 | $144.4M | +45.1% |
| FY2017 | $99.5M | +83.6% |
| FY2016 | $54.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SUPN financial trends
SUPN RevenueSUPN Net incomeSUPN Net marginSUPN Gross profitSUPN Gross marginSUPN Operating marginSUPN Operating cash flowSUPN Free cash flowSUPN Capital expendituresSUPN Return on equitySUPN Stock buybacksSUPN Dividends paidSUPN Total assetsSUPN Total liabilitiesSUPN Shareholders’ equitySUPN overview →